Dr. Andrew Gaya - Peer Reviewed Articles - updated July 2010
1) Gaya AM, Chisholm EM, Scott HJ, Donaldson DR ; ‘Perforated Diverticulitis Following Extra-Abdominal Surgery : Report of 3 cases’ . Postgraduate Medical Journal 1997 ; 73 : 739 – 740
2) Stebbing JJ, Gaya AM ; ‘The Evidence-Based Use Of Induction Chemotherapy In Breast Cancer’ . Breast Cancer 2001 ; 8 (1) : 23 – 37
3) Gaya AM, Rees J, Greenstein A, Stebbing JJ ; ‘The Use of Temozolomide in Recurrent Malignant Gliomas’ . Cancer Treatment Reviews 2002 ; 28 (2) : 115 – 120
4) Stebbing JJ , Gaya AM ; ‘Pegylated Liposomal Doxorubicin (Caelyx) In Recurrent Ovarian Cancer’ . Cancer Treatment Reviews 2002 ; 28 (2) : 121 – 125
5) Gaya AM , Ashford RFU ; ‘Cardiac Complications of Radiotherapy’ Clinical Oncology 2005 ; 17 (3) : 153 – 160
6) Gaya AM, Randle A , Ashford RFU ; ‘Right Ventricular Outflow Obstruction Secondary To Myocardial Metastases From Colorectal Cancer’. Clinical Oncology 2005 ; 17 (1) : 70 – 71
7) Gaya AM , Rustin GJS ; ‘Vascular Disrupting Agents – A new class of drug in Cancer Therapy’ Clinical Oncology 2005 ; 17 (4) : 277 – 290
8) Bower M, Gazzard B, Mandalia S, Newsom Davis T, Thirlwell C, Dhillon T, Young AM, Powles T, Gaya AM, Nelson M, Stebbing JJ ; ‘A Prognostic Index For Systemic AIDS – Related Lymphoma Treated In The Era Of Highly Active Anti Retroviral Therapy’. Annals Int. Med. 2005 ; 143 (4) : 265 – 273
9) Gaya AM , Rustin GJS ‘Clinical Progress In Tumor Vascular Disrupting Therapies’ . Chapter 17 of ‘Vascular Targeted Therapies In Oncology’; pp 305 – 322. Editor Siemann D ; Publisher, Wiley 2006. ISBN 0-470-01294-3
10) Stebbing J, Crane J, Gaya AM ; ‘Breast Cancer (Metastatic)’ . Clinical Evidence 2006 p 1 – 29. Also available online at http://www.clinicalevidence.com/ceweb/conditionpdf/0811.pdf
11) Jones B, Dale RG, Gaya AM; ‘Linear Quadratic Modelling Of Increased Late Normal Tissue Effects In Special Clinical Situations’ . Int J Radiat Oncol Biol Phys 2006 ; 64 (3) : 948 – 953
12) Walther J, Gaya AM, Korshid M, Plowman PN; ‘Crossover Response to Erlotinib Of Brain Metastatic Disease From Bronchial Adenocarcinoma After Gefitinib Failure, And An Unusual Rash’. Clinical Oncology 2006; 18 (8) : 637 – 638
13) Gaya AM, Daley F, Taylor NJ, Tozer G, Qureshi U, Padhani AR, Pedley RB, Begent R, Wellsted D, Stirling JJ, Richman P, Rustin GJS ; ‘Correlations Between Human Tumour Angiogenic Profile And Combretastatin-Induced Vascular Shutdown – An Exploratory Study. British Journal of Cancer 99(2):321-326 (2008)
14) S Hughes, J Liong, A Miah, S Ahmad, M Leslie, P Harper, J Prendiville, J Shamash, R Subramaniam, A Gaya, J Spicer, D Landau; Safety study of induction chemotherapy followed by synchronous radiotherapy (RT) and cetuximab in stage III non-small cell lung cancer (NSCLC): SCRATCH Study (Cohort 1). J. Thoracic Oncol. 3(6):648-651 (2008)
15) Acher PL, Rhode KS, Morris SL, Gaya AM, Miquel ME, Popert R, Nichol J, Tham IW, McLeish K, Deehan C, Dasgupta P, Beaney RP, Keevil SF ; ‘A Comparison of XMR Dosimetry And CT-based Dosimetry For The Evaluation of Permanent Prostate Brachytherapy Implants’. IJROBP 71(5):1518 – 1525 (2008)
16) Meyer T, Gaya AM, Dancey G, Stratford MR, Othman S, Sharma SK, Wellsted D, Taylor NJ, Stirling JJ, Poupard L, Folkes LK, Chan PS, Pedley RB, Chester KA, Owen K, Violet JA, Malaroda A, Green AJ, Buscombe J, Padhani AR, Rustin GJ, Begent RH. A phase I trial of radioimmunotherapy with 131I-A5B7 anti-CEA antibody in combination with combretastatin-A4-phosphate in advanced gastrointestinal carcinomas. Clin Cancer Res. 2009; 15(13) : 4484-92
17) G. J. Rustin, G. Shreaves, P. D. Nathan, A. Gaya, T. S. Ganesan, D. Wang, J. Boxall, L. Poupard, D. Chaplin, J. Balkissoon & M. Zweifel. A Phase Ib trial of CA4P (combretastatin A-4 phosphate) in combination with carboplatin and paclitaxel chemotherapy in patients with advanced cancer . Br J Cancer 2010; 102(9) : 1355 - 60
18) Martin A, Gaya AM. Stereotactic Body Radiotherapy: A Review. Clinical Oncol (R Coll Radiol) 2010; 22(3) : 157 - 72
19) Eichholz A, Merchant S, Gaya AM. Anti-angiogenesis therapies: their potential in cancer management. OncoTargets And Therapy 2010; 3 : 69-82
20) Acher P, Puttagunta S, Rhode K, Morris S, Kinsella J, Gaya A, Dasgupta P, Deehan C, Beaney R, Popert R, Keevil S. An analysis of intraoperative versus post-operative dosimetry with CT, CT-MRI fusion and XMR for the evaluation of permanent prostate brachytherapy implants. Radiotherapy & Oncology 2010;
21) Andrew M Gaya , N Jane Taylor , Tarun Mittal , J James Stirling, David J Collins , James d’Arcy, Gordon J Rustin, Tim Meyer, David Wellsted, Anwar R Padhani. Cardiac output changes, Interpatient and Intrapatient variability of DCE-MRI response of metastases following infusion of the vascular disruptive agent Combretastatin-A4 Phosphate (CA4P). Br J Cancer (Submitted)
Abstracts
1) Gaya AM, Nathan PD, Boxall J, Saunders L, Ganesan TS, Wang D, Rustin GJS ; ‘A Phase Ib Trial of Combretastatin A4 Phosphate (CA4P) In Combination With Carboplatin or Paclitaxel Chemotherapy In Patients With Advanced Cancer.’ The Tumour Microenvironment – Hypoxia, Angiogenesis & Vasculature 9th International Workshop 2005, Oxford, UK
2) Gaya AM, Nathan PD, Boxall J, Saunders L, Ganesan TS, Wang D, Rustin GJS ; ‘Update of a Phase I Trial of CA4P In Combination With Carboplatin or Paclitaxel Chemotherapy In Patients With Advanced Cancer.’ ; NCRI Cancer Conference (Birmingham) 2005
3) Rustin GJS, Nathan PD, Boxall J, Saunders L, Ganesan TS, Wang D, Gaya AM ; ‘A dose escalation study combining combretastatin A 4 phosphate (CA4P) with carboplatin or paclitaxel in patients with advanced cancer’ ; AACR-NCI-EORTC Conference On Molecular Targets And Cancer Therapeutics 2005, Philadelphia, USA
4) Andrew Gaya, Gairin Dancey, Mike Stratford, Shokri Othman, Marivic Ricamara Surinder Sharma, Jane Boxall, Linda Poupard, John Violet, Alan Green, Anwar Padhani, Gordon Rustin, Richard Begent, Tim Meyer; ‘A Phase I/II Trial of Radioimmunotherapy (RIT) with 131Iodine-Labelled A5B7 Anti-CEA Antibody (131I-A5B7) in Combination with Combretastatin-A4-Phosphate (CA4P) In Advanced Gastrointestinal Carcinomas’ ASCO Meeting J Clin Oncol 26 May 20 suppl; abstr 14517 (2008)
5) A. Gaya, N.J. Taylor, J.J. Stirling, G. Rustin, A. Padhani, V. Goh; ‘Early & Late Tumour Vasculature Changes Following the Vascular Disruptive Agent (VDA) Combretastatin-A4-Phosphate (CA4P) Using Dynamic Contrast Enhanced MRI (DCE-MRI) and Perfusion CT’ ESGAR 2008, Istanbul, Turkey, Abstract 31227
6) Nyree Griffin, Jyoti Parikh, Robert Johnstone, Andrew King, David Landau, Andrew Gaya, Geoff Charles-Edwards. Dynamic contrast-enhanced (DCE-) MRI of rectal cancer at 3-Tesla: initial experience and reproducibility of technique.Poster SE-024 ESGAR Meeting 2010, Dresden, Germany